Skip to main content
Mijn bibliotheek
Ga naar:
Nieuws Boeken Tijdschriften Toetsvragen Web-tv Video Audio
Tips voor Mijn BSL
BSL Shop
Inloggen

Welkom bij Erasmus MC & Bohn Stafleu van Loghum

Erasmus MC heeft ervoor gezorgd dat je Mijn BSL eenvoudig en snel kunt raadplegen. Je kunt je links eenvoudig registreren. Met deze gegevens kun je thuis, of waar ook ter wereld toegang krijgen tot Mijn BSL.

» Andere revante producten voor Erasmus MC studenten en medewerkers.

Registreer

Om ook buiten de locaties van Erasmus MC, thuis bijvoorbeeld, van Mijn BSL gebruik te kunnen maken, moet je jezelf eenmalig registreren. Dit kan alleen vanaf een computer op een van de locaties van Erasmus MC.

Eenmaal geregistreerd kun je thuis of waar ook ter wereld onbeperkt toegang krijgen tot Mijn BSL.

Login

Als u al geregistreerd bent, hoeft u alleen maar in te loggen om onbeperkt toegang te krijgen tot Mijn BSL.

Inloggen
Top
Quality of Life Research
Gepubliceerd in:

06-07-2023

Quality of life in the year after new diagnosis with advanced prostate cancer for Black and White individuals living in the US

Auteurs: Emily M. Rencsok, Natalie Slopen, Karen Autio, Alicia Morgans, Lawrence McSwain, Pedro Barata, Heather H. Cheng, Robert Dreicer, Elisabeth Heath, Rana R. McKay, Mark Pomerantz, Dana Rathkopf, Scott Tagawa, Young E. Whang, Camille Ragin, Folakemi T. Odedina, Daniel J. George, Philip W. Kantoff, Jacob Vinson, Paul Villanti, Sebastien Haneuse, Lorelei A. Mucci, The IRONMAN Registry

Gepubliceerd in: Quality of Life Research | Uitgave 11/2023

Log in om toegang te krijgen
share
DELEN

Deel dit onderdeel of sectie (kopieer de link)

  • Optie A:
    Klik op de rechtermuisknop op de link en selecteer de optie “linkadres kopiëren”
  • Optie B:
    Deel de link per e-mail
    Link delen
publish
Publiceer nu

Abstract

Purpose

To assess differences in baseline and longitudinal quality of life among Black and White individuals in the US with advanced prostate cancer.

Methods

Secondary analysis of data from the International Registry for Men with Advanced Prostate Cancer (IRONMAN) including US participants newly diagnosed with advanced prostate cancer and identifying their race as Black or White from 2017 to 2023. Participants completed the EORTC QLQ-C30 Quality of Life (QoL) Survey at study enrollment and every 3 months thereafter for up to 1 year of follow-up reporting 15 scale scores ranging from 0 to 100 (higher functioning and lower symptom scores represent better quality of life). Linear mixed effects models with race and month of questionnaire completion were fit for each scale, and model coefficients were used to assess differences in baseline and longitudinal QoL by race.

Results

Eight hundred and seventy-nine participants were included (20% identifying as Black) at 38 US sites. Compared to White participants at baseline, Black participants had worse constipation (mean 6.3 percentage points higher; 95% CI 2.9–9.8), financial insecurity (5.7 (1.4–10.0)), and pain (5.1 (0.9–9.3)). QoL decreased over time similarly by race; most notably, role functioning decreased by 0.7 percentage points (95% CI −0.8, −0.5) per month.

Conclusion

There are notable differences in quality of life at new diagnosis of advanced prostate cancer for Black and White individuals, and quality of life declines similarly in the first year for both groups. Interventions that address specific aspects of quality of life in these patients could meaningfully improve the overall survivorship experience.
vorige artikel Health-related quality of life among people who inject drugs in Australia
volgende artikel Measuring context that matters: validation of the modular Tele-QoL patient-reported outcome and experience measure
Bijlagen
Alleen toegankelijk voor geautoriseerde gebruikers
Literatuur
1.
2.
Chornokur, G., Dalton, K., Borysova, M. E., & Kumar, N. B. (2011). Disparities at presentation, diagnosis, treatment, and survival in African American men, affected by prostate cancer. Prostate, 71(9), 985–997.CrossRefPubMed
3.
Lillard, J. W., Moses, K. A., Mahal, B. A., & George, D. J. (2022). Racial disparities in Black men with prostate cancer: A literature review. Retrieved 15 May 2023, from https://​acsjournals.​onlinelibrary.​wiley.​com/​doi/​https://​doi.​org/​10.​1002/​cncr.​34433
4.
5.
Basch, E., Deal, A. M., Dueck, A. C., Scher, H. I., Kris, M. G., Hudis, C., & Schrag, D. (2017). Overall survival results of a trial assessing patient-reported outcomes for symptom monitoring during routine cancer treatment. JAMA, 318(2), 197–198.CrossRefPubMedPubMedCentral
6.
Husson, O., de Rooij, B. H., Kieffer, J., Oerlemans, S., Mols, F., Aaronson, N. K., van der Graaf, W. T. A., & van de Poll-Franse, L. V. (2020). The EORTC QLQ-C30 summary score as prognostic factor for survival of patients with cancer in the “real-world”: Results from the population-based PROFILES registry. The Oncologist, 25(4), e722.CrossRefPubMed
7.
8.
Eton, D. T., Lepore, S. J., Helgeson, V. S., Schulz, R., Hrebinko, R., Cohen, J., Hakala, R., Salup, R., Bonci, L., Trump, D., Lutins, J., Brufsky, A., Franz, J., Camp-anella, S., Long, S., Schwartz, R., Miller, R., & Benoit, R. (2001). Early quality of life in patients with localized prostate carcinoma an examination of treatment-related, demographic and psychosocial factors. Cancer, 92, 1451–1459.CrossRefPubMed
9.
Rice, K., Hudak, J., Peay, K., Elsamanoudi, S., Travis, J., Lockhart, R., Cullen, J., Black, L., Houge, S., & Brassell, S. (2010). Comprehensive quality-of-life outcomes in the setting of a multidisciplinary, equal access prostate cancer clinic. Urology, 76(5), 1231–1238.CrossRefPubMed
10.
Chhatre, S., Wein, A. J., Malkowicz, S. B., & Jayadevappa, R. (2011). Racial differences in well-being and cancer concerns in prostate cancer patients. Journal of Cancer Survivorship., 5(2), 182–190.CrossRefPubMed
11.
Cella, D., Ivanescu, C., Holmstrom, S., Bui, C. N., Spalding, J., & Fizazi, K. (2015). Impact of enzalutamide on quality of life in men with metastatic castration-resistant prostate cancer after chemotherapy: Additional analyses from the AFFIRM randomized clinical trial. Annals of Oncology., 26(1), 179–185.CrossRefPubMed
12.
Saad, F., Cella, D., Basch, E., Hadaschik, B. A., Mainwaring, P. N., Oudard, S., Graff, J. N., Mcquarrie, K., Li, S., Hudgens, S., Lawson, J., Lopez-Gitlitz, A., Yu, M. K., Smith, M. R., & Small, E. J. (2018). Effect of apalutamide on health-related quality of life in patients with non-metastatic castration-resistant prostate cancer: An analysis of the SPARTAN randomised, placebo-controlled, phase 3 trial. The Lancet Oncology, 19, 1404–1420.CrossRefPubMed
13.
Agarwal, N., Mcquarrie, K., Bjartell, A., Chowdhury, S., Pereira, A. J., Gomes, S., Chung, H., Ozguroglu, M., Soto, A. J., Merseburger, A. S., Uemura, H., Ye, D., Given, R., Cella, D., Basch, E., Miladinovic, B., Dearden, L., Deprince, K., Naini, V., … Chi, K. N. (2019). Health-related quality of life after apalutamide treatment in patients with metastatic castration-sensitive prostate cancer (TITAN): A randomised, placebo-controlled, phase 3 study. The Lancet Oncology, 20, 1518–1530.CrossRefPubMed
14.
Feyerabend, S., Saad, F., Li, T., Ito, T., Diels, J., Van Sanden, S., De Porre, P., Roiz, J., Abogunrin, S., Koufopoulou, M., & Fizazi, K. L. (2018). Survival benefit, disease progression and quality-of-life outcomes of abiraterone acetate plus prednisone versus docetaxel in metastatic hormone-sensitive prostate cancer: A network meta-analysis. European Journal of Cancer, 103, 78–87.CrossRefPubMed
15.
Sullivan, P. W., Mulani, P. M., Fishman, M., & Sleep, D. (2007). Quality of life findings from a multicenter, multinational, observational study of patients with metastatic hormone-refractory prostate cancer. Quality of Life Research, 16(4), 571–575.CrossRefPubMed
16.
Zajdlewicz, L., Hyde, M. K., Lepore, S. J., Gardiner, R. A., & Chambers, S. K. (2017). Health-related quality of life after the diagnosis of locally advanced or advanced prostate cancer: A longitudinal study. Cancer Nursing, 40(5), 412–419.CrossRefPubMed
17.
Mucci, L. A., Vinson, J., Gold, T., Gerke, T., Filipenko, J., Green, R. M., Anderson, S. G., Badal, S., Bjartell, A., Chi, K. N., Davis, I. D., Enting, D., Fay, A. P., Lazarus, J., Mateo, J., McDermott, R., Odedina, F. T., Olmos, D., Omlin, A., & George, D. J. (2022). IRONMAN: A novel international registry of men with advanced prostate cancer. JCO Global Oncology. https://​doi.​org/​10.​1200/​GO.​22.​00154CrossRefPubMedPubMedCentral
18.
19.
Shih, C. L., Chen, C. H., Sheu, C. F., Lang, H. C., & Hsieh, C. L. (2013). Validating and improving the reliability of the EORTC QLQ-C30 using a multidimensional Rasch model. Value in Health, 16(5), 848–854.CrossRefPubMed
20.
Ford, M. E., Havstad, S. L., & Kart, C. S (2001). Assessing the reliability of the EORTC QLQ-C30 in a sample of older African American and Caucasian adults. Qual Life Res, 10(6), 533–541.
21.
22.
Gamper, E. M., Musoro, J. Z., Coens, C., Stelmes, J. J., Falato, C., Groenvold, M., Velikova, G., Cocks, K., Flechtner, H. H., King, M. I. T., & Bottomley, A. (2021). Minimally important differences for the EORTC QLQ-C30 in prostate cancer clinical trials. BMC Cancer, 21(1), 1083.CrossRefPubMedPubMedCentral
23.
EORTC Data Center. (2001). EORTC QLQ-C30 scoring manual, 3rd edn.
24.
Azur, M. J., Stuart, E. A., Frangakis, C., & Leaf, P. J. (2011). Multiple imputation by chained equations: What is it and how does it work? International Journal of Methods in Psychiatric Research, 20(1), 40–49.CrossRefPubMedPubMedCentral
25.
Kaufman, J. S., & Cooper, R. S. (2001). Commentary: Considerations for use of racial/ethnic classification in etiologic research. American Journal of Epidemiology, 154(4), 291–298.CrossRefPubMed
26.
Little, R. J., & Rubin, D. B. (2014). Statistical analysis with missing data (2nd ed.). John Wiley & Sons.
27.
28.
Jayadevappa, R., Johnson, J. C., Chhatre, S., Wein, A. J., & Malkowicz, S. B. (2007). Ethnic variation in return to baseline values of patient-reported outcomes in older prostate cancer patients. Cancer, 109(11), 2229–2238.CrossRefPubMed
29.
Litwin, M. S., Mcguigan, K. A., Shpall, A. I., & Dhanani, N. (1999). Recovery of health related quality of life in the year after radical prostatectomy: Early experience. Journal of Urology., 161, 515–519.CrossRefPubMed
30.
Johnson, T. K., Gilliland, F. D., Hoffman, R. M., Deapen, D., Penson, D. F., Stanford, J. L., Albertsen, P. C., & Hamilton, A. S. (2004). Racial/ethnic differences in functional outcomes in the 5 years after diagnosis of localized prostate cancer. Journal of Clinical Oncology, 22(20), 4193–4201.CrossRefPubMed
31.
Halbert, C. H., Coyne, J., Weathers, B., Mahler, B., Delmoor, E., Vaughn, D., Malkowicz, S. B., Lee, D., & Troxel, A. (2010). Racial differences in quality of life following prostate cancer diagnosis. Urology, 76(3), 559–564.CrossRefPubMed
32.
Ravi, P., Karakiewicz, P. I., Roghmann, F., Gandaglia, G., Choueiri, T. K., Menon, M., McKay, R. R., Nguyen, P. L., Sammon, J. D., Sukumar, S., Varda, B., Chang, S. L., Kibel, A. S., Sun, M., & Trinh, Q. D. (2014). Mental health outcomes in elderly men with prostate cancer. Urologic Oncology: Seminars and Original Investigations, 32(8), 1333–1340.CrossRefPubMed
33.
Erim, D. O., Bensen, J. T., Mohler, J. L., Fontham, E. T. H., Song, L., Farnan, L., Delacroix, S. E., Peters, E. S., Erim, T. N., Chen, R. C., & Gaynes, B. N. (2019). Patterns and predictors of self-reported clinical diagnosis and treatment for depression in prostate cancer survivors. Cancer Medicine, 8(8), 3648–3658.CrossRefPubMedPubMedCentral
34.
Eylem, O., Eylem, O., De Wit, L., Van Straten, A., Steubl, L., Melissourgaki, Z., Danlsman, G. T., De Vries, R., Kerkhof, A. J. F. M., Bhui, K., & Cuijpers, P. (2020). Stigma for common mental disorders in racial minorities and majorities a systematic review and meta-analysis. BMC Public Health, 20(1), 1–20. https://​doi.​org/​10.​1186/​s12889-020-08964-3CrossRef
35.
Dickey, S. L., & Ogunsanya, M. E. (2018). Quality of life among black prostate cancer survivors: An integrative review. American Journal of Men’s Health, 12(5), 1648.CrossRefPubMedPubMedCentral
36.
Chatters, L. M., Taylor, R. J., Bullard, K. M., & Jackson, J. S (2009). Race and ethnic differences in religious involvement: African Americans, Caribbean Blacks and non-Hispanic Whites. Ethn Racial Stud, 32(7), 1143–1163.
37.
Beebe-Dimmer, J. L., Ruterbusch, J. J., Cooney, K. A., Bolton, A., Schwartz, K., Schwartz, A. G., & Heath, E. (2019). Racial differences in patterns of treatment among men diagnosed with de novo advanced prostate cancer: A SEER-medicare investigation. Cancer Medicine, 8(6), 3325.CrossRefPubMedPubMedCentral
38.
Khalaf, D. J., Sunderland, K., Eigl, B. J., Kollmannsberger, C. K., Ivanov, N., Finch, D. L., Oja, C., Vergidis, J., Zulfiqar, M., Gleave, M. E., & Chi, K. N. (2019). Health-related quality of life for abiraterone plus prednisone versus enzalutamide in patients with metastatic castration-resistant prostate cancer: Results from a phase II randomized trial. European Urology, 2019(75), 940–947. https://​doi.​org/​10.​1016/​j.​eururo.​2018.​12.​015CrossRef
39.
Stenzl, A., Dunshee, C., De Giorgi, U., Alekseev, B., Iguchi, T., Szmulewitz, R. Z., Flaig, T. W., Tombal, B., Morlock, R., Ivanescu, C., Ramawamy, K., Saad, F., & Armstrong, A. J. (2020). Effect of enzalutamide plus androgen deprivation therapy on health-related quality of life in patients with metastatic hormone-sensitive prostate cancer: An analysis of the ARCHES randomised, placebo-controlled, phase 3 study. European Urology, 78(4), 603–614.CrossRefPubMed
40.
Boevé, L., Hulshof, M. C. C. M., Verhagen, P. C. M. S., Twisk, J. W. R., Witjes, W. P. J., de Vries, P., van Moorselaar, R. J. A., van Andel, G., & Vis, A. N. (2021). Patient-reported quality of life in patients with primary metastatic prostate cancer treated with androgen deprivation therapy with and without concurrent radiation therapy to the prostate in a prospective randomised clinical trial; data from the HORRAD trial. European Urology, 79(2), 188–197.CrossRefPubMed
41.
Rush, H. L., Murphy, L., Morgans, A. K., Clarke, N. W., Cook, A. D., Attard, G., Macnair, A., Dearnaley, D. P., Parker, C. C., Russell, J. M., Gillessen, S., Matheson, D., Millman, R., Brawley, C. D., Pugh, C., Tanguay, J. S., Jones, R. J., Wagstaff, J., Rudman, S., & Langley, R. E. (2022). Quality of life in men with prostate cancer randomly allocated to receive docetaxel or abiraterone in the STAMPEDE trial. Journal of Clinical Oncology, 40(8), 825–836.CrossRefPubMed
42.
43.
44.
Richardson, L. D., & Norris, M. (2010). Access to health and health care: How race and ethnicity matter. Mount Sinai Journal of Medicine: A Journal of Translational and Personalized Medicine, 77(2), 166–177.CrossRef
45.
Morgans, A. K., Van Bommel, A. C. M., Stowell, C., Abrahm, J. L., Basch, E., Bekelman, J. E., Berry, D. L., Bossi, A., Davis, I. D., de Reijke, T. M., Denis, L. J., Evans, S. M., Fleshner, N. E., George, D. J., Kiefert, J., Lin, D. W., Matthew, A. G., McDermott, R., Payne, H., & Penson, D. F. (2015). Development of a standardized set of patient-centered outcomes for advanced prostate cancer: An international effort for a unified approach. European Urology, 68(5), 891–898.CrossRefPubMed
46.
Ford, M. E., Havstad, S. L., & Kart, C. S. (2001). Assessing the reliability of the EORTC QLQ-C30 in a sample of older African American and Caucasian adults. Quality of Life Research., 10, 533–541.CrossRefPubMed
Metagegevens
Titel
Quality of life in the year after new diagnosis with advanced prostate cancer for Black and White individuals living in the US
Auteurs
Emily M. Rencsok
Natalie Slopen
Karen Autio
Alicia Morgans
Lawrence McSwain
Pedro Barata
Heather H. Cheng
Robert Dreicer
Elisabeth Heath
Rana R. McKay
Mark Pomerantz
Dana Rathkopf
Scott Tagawa
Young E. Whang
Camille Ragin
Folakemi T. Odedina
Daniel J. George
Philip W. Kantoff
Jacob Vinson
Paul Villanti
Sebastien Haneuse
Lorelei A. Mucci
The IRONMAN Registry
Publicatiedatum
06-07-2023
Uitgeverij
Springer International Publishing
Gepubliceerd in
Quality of Life Research / Uitgave 11/2023
Print ISSN: 0962-9343
Elektronisch ISSN: 1573-2649
DOI
https://doi.org/10.1007/s11136-023-03468-0

Andere artikelen Uitgave 11/2023

Health-related quality of life profiles in adolescents and young adults with chronic conditions

Improving the quality of life of parents of patients with congenital abnormalities using psychoeducational interventions: a systematic review

  • Open Access
  • Review

Associations between treatments, comorbidities and multidimensional aspects of quality of life among patients with advanced cancer in the Netherlands—a 2017–2020 multicentre cross-sectional study

  • Open Access

Understanding the measurement relationship between EQ-5D-5L, PROMIS-29 and PROPr

  • Open Access

Comparison of latent variable and psychological network models in PROMIS data: output metrics and factor structure

How well do the adult social care outcomes toolkit for carers, carer experience scale and care-related quality of life capture aspects of quality of life important to informal carers in Australia?

  • Open Access